The current state of prostate-specific antigen testing

被引：4

作者：

Lewis, Ryan ^{[1
]}

Hornberger, Brad ^{[2
]}

机构：

[1] Univ Texas Southwestern Med Ctr, PA Postgrad Urol Training Program, Dallas, TX 75390 USA

[2] Univ Texas Southwestern Med Ctr, PA Postgrad Urol Training Program, Dept Urol, Dallas, TX USA

来源：

JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS | 2016年 / 29卷 / 09期

关键词：

prostate-specific antigen; PSA; testing; prostate cancer; guidelines; US Preventive Services Task Force; CANCER MORTALITY; FOLLOW-UP; TRIAL; PSA; RECOMMENDATION; PREDICTOR; RATES; LUNG;

D O I：

10.1097/01.JAA.0000490955.33308.6e

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Since prostate-specific antigen (PSA) testing was approved in 1994, the incidence of metastasis and mortality from prostate cancer have significantly decreased. However, PSA screening for prostate cancer has limitations and few large randomized controlled trials have been conducted to determine the mortality benefit of PSA screening. Two studies that have been conducted are the Prostate, Lung, Colorectal, and Ovarian (PLCO) screening trial and the European Randomized Study of Screening for Prostate Cancer (ERSPC). These were the two main studies the US Preventive Services Task Force (USPSTF) used in its recommendation against prostate cancer screening in 2012. However, new evidence has demonstrated that the PLCO trial had signifi cant limitations and the results of the ERSPC trial were more significant than previously thought. This article describes the strengths and weaknesses of the USPSTF's recommendation, along with current guidelines for prostate cancer screening.

引用

页码：51 / 53

页数：3

共 16 条

[1]

American Cancer Society, LIF RISK DEV DYING C

[2]

American Cancer Society, KEY STAT PROST CANC

[3] Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up [J].

Andriole, Gerald L. ;

Crawford, E. David ;

Grubb, Robert L., III ;

Buys, Saundra S. ;

Chia, David ;

Church, Timothy R. ;

Fouad, Mona N. ;

Isaacs, Claudine ;

Kvale, Paul A. ;

Reding, Douglas J. ;

Weissfeld, Joel L. ;

Yokochi, Lance A. ;

O'Brien, Barbara ;

Ragard, Lawrence R. ;

Clapp, Jonathan D. ;

Rathmell, Joshua M. ;

Riley, Thomas L. ;

Hsing, Ann W. ;

Izmirlian, Grant ;

Pinsky, Paul F. ;

Kramer, Barnett S. ;

Miller, Anthony B. ;

Gohagan, John K. ;

Prorok, Philip C. .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (02) :125-132

[4]

[Anonymous], DET PROST CANC

[5]

[Anonymous], NCCN CLIN PRACTICE G

[6] Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States [J].

Barocas, Daniel A. ;

Mallin, Katherine ;

Graves, Amy J. ;

Penson, David F. ;

Palis, Bryan ;

Winchester, David P. ;

Chang, Sam S. .

JOURNAL OF UROLOGY, 2015, 194 (06) :1587-1593

[7] Prostate-specific Antigen-Based Prostate Cancer Screening: Reduction of Prostate Cancer Mortality After Correction for Nonattendance and Contamination in the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer [J].

Bokhorst, Leonard P. ;

Bangma, Chris H. ;

van Leenders, Geert J. L. H. ;

Lous, Jan J. ;

Moss, Sue M. ;

Schroder, Fritz H. ;

Roobol, Monique J. .

EUROPEAN UROLOGY, 2014, 65 (02) :329-336

[8] National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening [J].

Drazer, Michael W. ;

Huo, Dezheng ;

Eggener, Scott E. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (22) :2416-U18

[9] Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations [J].

Jemal, Ahmedin ;

Fedewa, Stacey A. ;

Ma, Jiemin ;

Siegel, Rebecca ;

Lin, Chun Chieh ;

Brawley, Otis ;

Ward, Elizabeth M. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (19) :2054-2061

[10] BASELINE PSA BEFORE AGE 60 AS A PREDICTOR OF IMPORTANT PROSTATE CANCER DIAGNOSIS AND PROSTATE CANCER-SPECIFIC MORTALITY IN THE INTERVENTION ARM OF THE PROSTATE, LUNG, COLORECTAL AND OVARIAN TRIAL [J].

Kovac, Evan ;

Carlsson, Sigrid ;

Lilja, Hans G. ;

Hugosson, Jonas ;

Kattan, Michael ;

Holmberg, Erik ;

Stephenson, Andrew J. .

JOURNAL OF UROLOGY, 2016, 195 (04) :E545-E546

← 1 2 →